Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 589-600 of 4,306
Drug study icon
CompletedNCT00297388

How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections for schizophrenia

This study is completed. It is testing How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections for schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 70 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Drug study icon
CompletedNCT01143090

Subjects Switched to Lurasidone for schizophrenia

This study is completed in the United States. It is testing subjects Switched to Lurasidone for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugOver 18 Years
Countries
United States
Sponsor
Sumitomo Pharma America, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT00206102

Cataractogenic Potential of Seroquel and Risperdal for schizophrenia

This study is completed in the United States. It is testing cataractogenic Potential of Seroquel and Risperdal for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
AstraZeneca
Condition
Schizophrenia
Drug study icon
CompletedNCT00649064

Effects of Ziprasidone for schizophrenia

This study is completed in Taiwan. It is testing effects of Ziprasidone for schizophrenia.

Multiple locations, including Changhua
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Taiwan
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT00650429

Ziprasidone for schizophrenia

This study is completed in Mexico. It is testing ziprasidone for schizophrenia.

Multiple locations, including Monterrey
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 70 Years
Countries
Mexico
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT00645229

Ziprasidone for schizophrenia

This study was terminated in Portugal. It is testing ziprasidone for schizophrenia.

In Lisbon
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 60 Years
Countries
Portugal
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.